A brand new report by EY has revealed that regardless of tariff uncertainty, the medtech business has recorded its seventh successive 12 months of top-line progress to succeed in a valuation of $584bn within the 12 months ended 30 June, with the sector on track to document 6% to 7% income progress by the tip of 2025.
EY’s Pulse of the MedTech Business report discovered that medtech VC investments have been up 16% within the first half of the 12 months in contrast with the identical interval in 2024, with common financing rounds reaching $36m, reflecting a 122% improve over 2024.
The report famous that VC funding within the business has been characterised by focus in particular financing rounds, with corporations concentrating on high-growth belongings.
“Medtech continues to ship regular progress, and efficiency is being pushed by innovation and market enlargement in high-growth areas resembling pulsed discipline ablation (PFA), structural coronary heart, robotics, diabetes and orthopaedics,” defined John Babitt, EY’s international medical know-how chief.
Notable investments throughout EY’s report interval embody Canadian PFA system firm Kardium securing C$340m ($250m) and British robotic surgical procedure firm CMR Surgical attracting fairness and debt capital of round $200m.
Babitt continued: “The [medtech] sector is proving to be a secure harbour inside the comparatively underperforming broader healthcare business, producing stronger outcomes and constructing confidence for the quarters forward.”
On the M&A entrance, EY’s report noticed a pattern towards “extra considered” dealmaking, noting that whereas the variety of offers has not elevated in contrast with 2024, the typical deal worth is on the rise.
General M&A spending for 2025 so far stood at $38.8bn, with the typical deal measurement of $497m reflecting an 11% and 72% rise from the typical throughout 2024 and over the earlier decade, respectively.
The largest offers of the 12-month interval to June 30 included Stryker’s $4.9bn acquisition of Inari Medical, Johnson & Johnson’s $1.7bn transfer for Israel’s V‑Wave, and Edwards’ mixed $1.2bn deal for Endotronix and JenaValve.
The figures point out that in within the 12 months to 30 June, M&A exercise is concentrated on “fewer however extra significant alternatives”, EY Americas life sciences chief Arda Ural highlighted throughout a media webinar on the report’s key findings.
Concerning preliminary public choices (IPO), whereas within the report’s surveyed interval there has solely been round 5 medtech IPOs, together with Beta Bionics $204m IPO firstly of the 12 months and Kestra $204m IPO in March, John Babitt shared in the course of the webinar that there seems to be an ongoing urge for food for medtechs to go public.
